VR Logo

Neoleukin Therapeutics Inc. (NLTX) download report


Healthcare | Drugs & Pharma

Neoleukin Therapeutics Inc. (NLTX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology.

IPO Date: 07-Mar-2014

CEO, Pres, Principal Financial Officer & Director: Dr. Jonathan G. Drachman M.D.

Chief Medical Officer: Dr. Priti Patel M.D., M.S.

Listing: NASDAQ: NLTX

Country: United States

Headquarters: Seattle, WA

Website: https://www.neoleukin.com

Key Facts

Market cap: $43.35 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-61.09 Mln

Cash: $128.06 Mln

Total Debt: $12.71 Mln

Insider's Holding: 21.48%

Liquidity: Low

52 Week range: $0.80 - 9.75

Shares outstanding: 42,504,000

10 Years Aggregate:

  • CFO: $-247.29 Mln
  • EBITDA: $-308.85 Mln
  • Net Profit: $-344.51 Mln

Stock Performance

Time Period Neoleukin Therapeutics (NLTX) S&P BSE Healthcare S&P Small-Cap 600
YTD-79.46-17.04-18.78
1 month-0.99-3.24-8.00
3 months-47.34-10.55-13.65
1 Year-89.27-15.04-17.19
3 Years-25.1419.036.10
5 Years-41.198.915.87
10 Years--12.199.84
As on 01-Jul-2022
Year Neoleukin Therapeutics (NLTX) S&P Small-Cap 600 S&P BSE Healthcare
2021-65.8225.2720.87
202014.459.5761.45
2019470.3720.86-3.55
2018-81.46-9.70-5.89
2017-28.7711.730.49
201632.2924.74-12.88
201566.40-3.3615.06